Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first line treatment of patients with metastatic colorectal cancer - the AFFIRM study.
Authors
Folprecht, GPericay, C
Saunders, Mark P
Thomas, A
Lopez, R
Roh, J
Chistyakov, V
Höhler, T
Kim, J
Hofheinz, R
Ackland, S
Swinson, D
Kopp, M
Udovitsa, D
Hall, M
Iveson, T
Vogel, A
Zalcberg, J
Affiliation
University Cancer Center / Medical Department I, University Hospital Carl Gustav Carus, Dresden, GermanyIssue Date
2016-04-18
Metadata
Show full item recordAbstract
The combination of aflibercept with FOLFIRI has been shown to significantly prolong overall survival in patients with metastatic colorectal cancer (mCRC) after progression on oxaliplatin-based therapy. This trial evaluated the addition of aflibercept to oxaliplatin-based first-line treatment of patients with mCRC.Citation
Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first line treatment of patients with metastatic colorectal cancer - the AFFIRM study. 2016: Ann OncolJournal
Annals of OncologyDOI
10.1093/annonc/mdw176PubMed ID
27091810Type
ArticleLanguage
enISSN
1569-8041ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdw176
Scopus Count
Collections
Related articles
- The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence.
- Authors: Wade R, Duarte A, Simmonds M, Rodriguez-Lopez R, Duffy S, Woolacott N, Spackman E
- Issue date: 2015 May
- Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial.
- Authors: Ruff P, Van Cutsem E, Lakomy R, Prausova J, van Hazel GA, Moiseyenko VM, Soussan-Lazard K, Dochy E, Magherini E, Macarulla T, Papamichael D
- Issue date: 2018 Jan
- Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as first‑line therapy for metastatic colorectal cancer: GERCOR VELVET phase II study.
- Authors: Chibaudel B, Bachet JB, André T, Auby D, Desramé J, Deplanque G, Lecaille C, Louvet C, Tournigand C, Lebrun-Ly V, Dauba J, Lledo G, Garcia ML, Dubreuil O, Hamed NB, Meurisse A, Larsen AK, Tijeras-Raballand A, Bonnetain F, De Gramont A
- Issue date: 2019 Apr
- Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G).
- Authors: Yamazaki K, Nagase M, Tamagawa H, Ueda S, Tamura T, Murata K, Eguchi Nakajima T, Baba E, Tsuda M, Moriwaki T, Esaki T, Tsuji Y, Muro K, Taira K, Denda T, Funai S, Shinozaki K, Yamashita H, Sugimoto N, Okuno T, Nishina T, Umeki M, Kurimoto T, Takayama T, Tsuji A, Yoshida M, Hosokawa A, Shibata Y, Suyama K, Okabe M, Suzuki K, Seki N, Kawakami K, Sato M, Fujikawa K, Hirashima T, Shimura T, Taku K, Otsuji T, Tamura F, Shinozaki E, Nakashima K, Hara H, Tsushima T, Ando M, Morita S, Boku N, Hyodo I
- Issue date: 2016 Aug
- Aflibercept.
- Authors: Ciombor KK, Berlin J, Chan E
- Issue date: 2013 Apr 15